154 related articles for article (PubMed ID: 11142478)
1. Phase II study of pegylated liposomal doxorubicin: inactive in recurrent small-cell lung cancer. A Hellenic Cooperative Oncology Group Study.
Samantas E; Kalofonos H; Linardou H; Nicolaides C; Mylonakis N; Fountzilas G; Kosmidis P; Skarlos D
Ann Oncol; 2000 Nov; 11(11):1395-7. PubMed ID: 11142478
[TBL] [Abstract][Full Text] [Related]
2. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
Charpidou A; Hatzidarellis EP; Alamara C; Dilana K; Pantazopoulos K; Kotteas E; Georgatou N; Syrigos KN
In Vivo; 2006; 20(4):553-7. PubMed ID: 16900789
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.
Caponigro F; Comella P; Budillon A; Bryce J; Avallone A; De Rosa V; Ionna F; Comella G
Ann Oncol; 2000 Mar; 11(3):339-42. PubMed ID: 10811502
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Skarlos DV; Samantas E; Briassoulis E; Panoussaki E; Pavlidis N; Kalofonos HP; Kardamakis D; Tsiakopoulos E; Kosmidis P; Tsavdaridis D; Tzitzikas J; Tsekeris P; Kouvatseas G; Zamboglou N; Fountzilas G
Ann Oncol; 2001 Sep; 12(9):1231-8. PubMed ID: 11697833
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.
Gogas H; Papadimitriou C; Kalofonos HP; Bafaloukos D; Fountzilas G; Tsavdaridis D; Anagnostopoulos A; Onyenadum A; Papakostas P; Economopoulos T; Christodoulou C; Kosmidis P; Markopoulos C
Ann Oncol; 2002 Nov; 13(11):1737-42. PubMed ID: 12419745
[TBL] [Abstract][Full Text] [Related]
8. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
9. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
10. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
11. Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck.
Faivre S; Alsabe H; Djafari L; Janot F; Julieron M; Domenge C; Djazouli K; Armand JP; Luboinski B; Raymond E
Eur J Cancer; 2004 Jul; 40(10):1517-21. PubMed ID: 15196535
[TBL] [Abstract][Full Text] [Related]
12. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
Perez AT; Domenech GH; Frankel C; Vogel CL
Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
[TBL] [Abstract][Full Text] [Related]
13. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
Coleman RE; Biganzoli L; Canney P; Dirix L; Mauriac L; Chollet P; Batter V; Ngalula-Kabanga E; Dittrich C; Piccart M
Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
18. NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.
Gregorc V; Cavina R; Novello S; Grossi F; Lazzari C; Capelletto E; Genova C; Salini G; Lambiase A; Santoro A
Oncologist; 2018 Oct; 23(10):1133-e112. PubMed ID: 30076277
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Janinis J; Stathopoulos GP; Nikolaidis P; Kalofonos HP; Kalogera-Fountzila A; Samantas E; Aravantinos G; Anagnostopoulos A; Tolis C; Makatsoris T; Rigatos SK; Bafaloukos D; Dimopoulos MA; Daniilidis J; Fountzilas G
Anticancer Drugs; 2004 Jun; 15(5):479-87. PubMed ID: 15166622
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
